Purchase this article with an account.
N. Pfeiffer, A. Troost, I. Kersten–Gomez, S. Miglior, V. Torri, T. Zeyen, J. Cunha–Vaz, I. Adamsonson, EGPS–Group; Central Corneal Thickness in the European Glaucoma Prevention Study (EGPS) . Invest. Ophthalmol. Vis. Sci. 2005;46(13):4862.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: The European Glaucoma Prevention Study (EGPS) was designed to test if lowering of intraocular pressure (IOP) by means of topical application of dorzolamide is able to prevent or delay conversion from ocular hypertension to glaucoma. Within this study we investigated central corneal thickness (CCT). Methods:We measured CCT in 854 ocular hypertensive patients using ultrasound pachymetry (DGH–500 pachymeter, PachetteTM). CCTs were taken a.m. before measuring intraocular pressure within 5 minutes of application of anaesthetic eye drops averaging 5 measurements per eye and both eyes of one patient. Results:We obtained CCT measurements in 854 patients. Mean CCT was 572.6 ± 37.4 µm (458.5 to 695.6 µm). 428 patients were on topical treatment with dorzolamide, and 425 patients were on placebo. Mean CCTs were 574.2 ± 38.48 µm (458.5 to 695.6 µm) for eyes on dorzolamide and 571.0 ± 36.21 µm (469.7 to 690.1 µm) for eyes on placebo (Wilcoxon two–sample test, p=0.31). Greater CCT measurements correlated with higher IOP, younger age, diabetes and female gender. Conclusions: CCT measurements within the European Glaucoma Prevention study were greater than in normal eyes without ocular hypertension. A trend for eyes on dorzolamide to have thicker corneas was both clinically and statistically not significant. Greater CCT measurements correlated with higher IOP, younger age, diabetes and female gender.
This PDF is available to Subscribers Only